With the wind of the pandemic at its back, the biopharma industry saw a surging tide of fundraising in 2020 that has only exponentially grown this year, Enpoint News writes. But with VC dollars flowing like never before, are there some cracks showing in biopharma’s gold-tinted façade? In the first half of 2021, total healthcare venture spending in the US has already outstripped 2020’s record-breaking totals across biotech, healthtech and beyond, putting the industry on a funding pace that could be hard to match in coming years, according to a new report from Silicon Valley Bank released Wednesday. Read more.
Related Posts
Sen. Bernie Sanders calls for $170B Investment to Boost Primary Care, Combat Staffing Shortages
The U.S. spends less than 7% of its healthcare budget on primary care. Most developed countries spend between 10% and 15%.
June 30, 2023
Insurance Companies are Being Sued by an ASC that had Enough
Since 2019, Coast Surgery Center accumulated bills totaling over $6 million in unpaid claims.
January 16, 2023
Hospitals Bet Big on Venture Capital Amid COVID-19 Revenue Flux
More hospitals — especially large nonprofit systems with substantial cash pools — are acting more like venture capitalists as they ramp up investments.
March 30, 2022
Microsoft’s Peter Lee on the Potential Benefits of GPT-4 on Healthcare
Lee, head of Microsoft Research, is tasked with assessing the implications of the tool for medicine. And he thinks it could increase efficiency and even empathy in the healthcare system, as well as boost biomedical research.
March 31, 2023